Shuttle Pharma's Selective HDAC Inhibitor Exhibits Ataxia-Telangiectasia Mutated Protein Activation And Modulation Of ER Expression Resulting In Growth Inhibition Of Estrogen Receptor Positive Breast Cancer Cells, As Reported In 'Public Library Of Science ONE'
Portfolio Pulse from Benzinga Newsdesk
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) announced the publication of a manuscript in PLOS ONE detailing the efficacy of its HDAC inhibitor, SP-1-303, in inhibiting the growth of estrogen receptor positive breast cancer cells. The study highlights the activation of ataxia-telangiectasia mutated protein and modulation of estrogen receptor expression by SP-1-303.
July 19, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) announced positive pre-clinical results for its HDAC inhibitor SP-1-303, which could potentially inhibit the growth of estrogen receptor positive breast cancer cells. This development is significant for the company's product pipeline and could positively impact its stock price.
The announcement of positive pre-clinical results for SP-1-303 is a significant milestone for Shuttle Pharma, as it demonstrates the potential efficacy of their product in treating estrogen receptor positive breast cancer. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100